# A Phase 1 Study of PPI-668 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) Genotype 1

> **NCT01448200** · PHASE1 · COMPLETED · sponsor: **Presidio Pharmaceuticals, Inc.** · enrollment: 82 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** PPI-668
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01448200
- **Lead sponsor:** Presidio Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2012-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01448200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01448200, "A Phase 1 Study of PPI-668 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) Genotype 1". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01448200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*